title: R-CHOEP-14 improves overall survival in young high-risk patients with diffuse large B-cell lymphoma compared with R-CHOP-14. A population-based investigation from the Danish Lymphoma Group.
abstract: BACKGROUND
  Optimal treatment of young patients with high-risk diffuse large B-cell lymphoma (DLBCL) remains a matter of debate and requires improvement. The combination chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) with addition of etoposide (CHOEP) has in other patient groups been shown to be effective. Further improvement has been accomplished with the use of rituximab in combination with the regimens every 2 weeks (R-CHOP-14, R-CHOEP-14). The aim of the present retrospective population-based study was to compare R-CHOP-14 with R-CHOEP-14 in a cohort of high-risk patients aged 18-60 years with two or more risk factors (stage III-IV, elevated lactate dehydrogenase levels, performance status 2-4). To our knowledge, this is the first study comparing these two regimens in this patient group.
  
  
  METHODS
  We obtained data for the period 2004-2009 from the Danish Lymphoma Database. One hundred and fifty-nine patients were eligible to enter the study. Primary end point was overall survival (OS) and secondary end points were response to treatment, progression-free survival (PFS) and safety.
  
  
  RESULTS
  Four-year OS was superior in the R-CHOEP-14 group: 75% compared with 62% for R-CHOP-14 (P=0.04). This superiority was also seen for PFS: 4-year PFS was 70% for the R-CHOEP-14 group compared with 58% for the R-CHOP-14 group (P=0.02).
  
  
  CONCLUSIONS
  R-CHOEP-14 is a promising regimen for young patients with high-risk DLBCL with improved OS and PFS compared with R-CHOP-14.
authors: Department of Haematology, Herlev Hospital, Herlev. Electronic address: mailto:aog@dadlnet.dk.
authors: A O
authors: AO
authors: Gang
authors: Department of Haematology, Rigshospitalet, Copenhagen.
authors: C
authors: C
authors: Strøm
authors: Department of Haematology, Herlev Hospital, Herlev.
authors: M
authors: M
authors: Pedersen
authors: Department of Haematology, Århus Hospital, Århus.
authors: F
authors: F
authors: d'Amore
authors: Department of Haematology, Odense Hospital, Odense.
authors: L M
authors: LM
authors: Pedersen
authors: Department of Haematology, Aalborg Hospital, Aalborg.
authors: A
authors: A
authors: Bukh
authors: Department of Haematology, Viborg Hospital, Viborg.
authors: B B
authors: BB
authors: Pedersen
authors: Department of Pathology, Odense Hospital, Odense.
authors: M B
authors: MB
authors: Moeller
authors: Department of Statistics and Analysis, The Danish IT Centre for Education and Research, UNI-C, Århus.
authors: L S
authors: LS
authors: Mortensen
authors: Department of Haematology, Vejle Hospital, Vejle.
authors: O V
authors: OV
authors: Gadeberg
authors: Department of Haematology, Næstved Hospital, Nl`stved.
authors: S
authors: S
authors: Ingeberg
authors: Department of Haematology, Esbjerg Hospital, Esbjerg.
authors: T
authors: T
authors: Mourits-Andersen
authors: Department of Haematology, Holstebro Hospital, Holstebro, Denmark.
authors: S
authors: S
authors: Pulczynski
authors: Department of Haematology, Rigshospitalet, Copenhagen.
authors: P D Nully
authors: PDN
authors: Brown
mesh_terms: D000328:Adult; D000368:Aged; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D003718:Denmark; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage; D016016:Proportional Hazards Models; D012042:Registries; D012189:Retrospective Studies; D012307:Risk Factors; D000069283:Rituximab; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab; D014750:Vincristine; D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone